Industry
Biotechnology
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
May 23, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 5:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 1:03 pm
Portfolio Pulse from Benzinga Insights
April 26, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
April 25, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
April 23, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 17, 2024 | 12:47 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 8:24 pm
Portfolio Pulse from Benzinga Insights
April 01, 2024 | 9:13 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.